GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (FRA:4YL) » Definitions » EV-to-FCF

Nanoform Finland (FRA:4YL) EV-to-FCF : -3.22 (As of Dec. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nanoform Finland's Enterprise Value is €65.55 Mil. Nanoform Finland's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €-20.37 Mil. Therefore, Nanoform Finland's EV-to-FCF for today is -3.22.

The historical rank and industry rank for Nanoform Finland's EV-to-FCF or its related term are showing as below:

FRA:4YL' s EV-to-FCF Range Over the Past 10 Years
Min: -31.35   Med: -7.47   Max: -2.27
Current: -3.63

During the past 8 years, the highest EV-to-FCF of Nanoform Finland was -2.27. The lowest was -31.35. And the median was -7.47.

FRA:4YL's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs FRA:4YL: -3.63

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), Nanoform Finland's stock price is €1.246. Nanoform Finland's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.270. Therefore, Nanoform Finland's PE Ratio (TTM) for today is At Loss.


Nanoform Finland EV-to-FCF Historical Data

The historical data trend for Nanoform Finland's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoform Finland EV-to-FCF Chart

Nanoform Finland Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - -25.15 -18.37 -6.47 -3.79

Nanoform Finland Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.98 -3.79 -8.20 -4.45 -4.61

Competitive Comparison of Nanoform Finland's EV-to-FCF

For the Biotechnology subindustry, Nanoform Finland's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoform Finland's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoform Finland's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Nanoform Finland's EV-to-FCF falls into.



Nanoform Finland EV-to-FCF Calculation

Nanoform Finland's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=65.547/-20.369
=-3.22

Nanoform Finland's current Enterprise Value is €65.55 Mil.
Nanoform Finland's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-20.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanoform Finland  (FRA:4YL) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Nanoform Finland's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.246/-0.270
=At Loss

Nanoform Finland's share price for today is €1.246.
Nanoform Finland's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.270.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Nanoform Finland EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoform Finland Business Description

Traded in Other Exchanges
Address
Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceuticals pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications.

Nanoform Finland Headlines

No Headlines